Description: BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.
Home Page: www.beyondspringpharma.com
BYSI Technical Analysis
28 Liberty Street
New York,
NY
10005
United States
Phone:
646 305 6387
Officers
| Name | Title |
|---|---|
| Dr. Lan Huang | Co-Founder, Chairman & CEO |
| Dr. G. Kenneth Lloyd | Chief Scientific Officer |
| Dr. Ramon W. Mohanlal | Exec. VP of R&D, Chief Medical Officer and Director |
| Mr. Linqing Jia | Co-Founder |
| Stephen Kilmer | Head of Investor Relations |
| Mr. Gregg Russo | Sr. VP of HR |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 10.5374 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.6777 |
| Price-to-Sales TTM: | 62.2401 |
| IPO Date: | 2017-03-09 |
| Fiscal Year End: | December |
| Full Time Employees: | 103 |